I am a
Home I AM A Search Login

Papers of the Week


Papers: 19 Feb 2022 - 25 Feb 2022


Pharmacology/Drug Development


2022 Mar-Apr


Pain Rep


7


2

The neurologic pain signature responds to nonsteroidal anti-inflammatory treatment vs placebo in knee osteoarthritis.

Authors

López-Solà M, Pujol J, Monfort J, Deus J, Blanco-Hinojo L, Harrison BJ, Wager TD
Pain Rep. 2022 Mar-Apr; 7(2):e986.
PMID: 35187380.

Abstract

Many drug trials for chronic pain fail because of high placebo response rates in primary endpoints. Neurophysiological measures can help identify pain-linked pathophysiology and treatment mechanisms. They can also help guide early stop/go decisions, particularly if they respond to verum treatment but not placebo. The neurologic pain signature (NPS), an fMRI-based measure that tracks evoked pain in 40 published samples and is insensitive to placebo in healthy adults, provides a potentially useful neurophysiological measure linked to nociceptive pain.